WO/2014/094844 LOCALIZED DISINFECTION SYSTEM FOR LARGE WATER BODIES||WO||26.06.2014|
||PCT/EP2012/076170||CRYSTAL LAGOONS (CURACAO) B.V.||FISCHMANN, Fernando Benjamin|
The present disclosure relates to a method for controlling the microbiological properties of a portion of water within a large body of water by treating such zone with chemical agents, according to the temperature of the water, its salinity, its dilution power and the diffusion of chemicals within the large water body.
WO/2014/063868 GALACTAGOGUE COMPOSITIONS BASED ON PHOSPHATIDYLSERINE||WO||01.05.2014|
||PCT/EP2013/069466||VELLEJA RESEARCH S.R.L.||DI PIERRO, Francesco|
The present invention relates to galactagogue compositions based on phosphatidylserine for use in the treatment of hypogalactia.
||PCT/EP2013/071247||H. LUNDBECK A/S||KILBURN, John Paul|
The present application relates to compounds of formula (I), wherein R1 to R5 are as defined in claim 1, a pharmaceutical composition thereof and said compounds for use in the treatment of diseases related with the activity of P2X7 receptor.
WO/2014/041195 GLUCAGON ANALOGUES||WO||20.03.2014|
||PCT/EP2013/069286||ZEALAND PHARMA A/S||TOLBORG, Jakob Lind|
The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
WO/2014/040837 ISOXAZOLIDINE DERIVATIVES||WO||20.03.2014|
||PCT/EP2013/067509||CHIESI FARMACEUTICI S.P.A.||GHIDINI, Eleonora|
The present invention relates to novel anti-inflammatory and antiallergic compounds of the glucocorticosteroid series, methods of preparing such compounds, pharmaceutical compositions comprising them, combinations and therapeutic uses thereof. More particularly, the invention relates to glucocorticosteroids that are derivatives of isoxazolidine.
WO/2014/037532 METHODS OF TREATING ALZHEIMER'S DISEASE AND PHARMACEUTICAL COMPOSITIONS THEREOF||WO||13.03.2014|
||PCT/EP2013/068516||H. LUNDBECK A/S||SCHMIDT, Ellen|
The present invention describes methods of treating dementia comprising administering an effective daily dose of N-(2-(6-fluoro-lH-indol-3-yl)ethyl-(2,2,3,3-tetrafluoropropoxy)benzylamine to improve or augment the effect of an acetylcholinesterase inhibitor.
WO/2014/039682 ANTIBODY FORMULATIONS AND USES THEREOF||WO||13.03.2014|
||PCT/US2013/058265||TRACON PHARMACEUTICALS, INC.||BENEDICT, Suzanne|
The present application relates to formulations of anti-CD 105 antibodies, antigen- binding fragments thereof, and uses thereof. Another aspect relates to pre-filled syringes of the formulations of anti-CD 105 antibodies or antigen-binding fragments thereof. Another aspect relates to the use of the formulations to reduce one or more signs or symptoms of an angiogenesis-related disorder such as cancers and ophthalmologic diseases.
WO/2014/033057 AEROSOL INHALATION DEVICE||WO||06.03.2014|
||PCT/EP2013/067514||CHIESI FARMACEUTICI S.P.A.||BRAMBILLA, Gaetano|
The invention deals with an actuator (1) for an aerosol inhalation device comprising a housing adapted to receive an aerosol canister (2) containing a pressurised medicament formulation, a mouthpiece portion through which the user inhales, a nozzle block (5), an orifice (8), and a tubular element (11) extending in the mouthpiece portion from the orifice aperture in a longitudinal axis aligned with a longitudinal axis of the mouthpiece portion. In particular said tubular element is positioned to enclose the orifice aperture within a recess. The tubular element is configured such that one of its terminal openings may be close fit to the nozzle block external surface, around the orifice aperture, so as to be in a continuous flow path with the orifice. Such configuration provides for a significant reduction in the non-respirable, coarse fraction of the emitted aerosol medicament via inertial impaction and retention in the actuator than in the oro-pharynx, with consequent less associated side effects and oral candidiasis in the patient. The presence of the tubular element has minimal, negligible impact on the fine particle dose and on the particle size distribution (PSD) of the delivered particles having aerodynamic diameter lower than 9 μm.
WO/2014/033330 A METHOD FOR SELECTION OF AGENTS INFLUENCING INTESTINAL MOTILITY DISORDERS AND PAIN||WO||06.03.2014|
||PCT/EP2013/068202||BioGaia AB||CONNOLLY, Eamonn|
A method is provided for evaluating agents for the treatment of different intestinal motility disorders, using distinct methodological parts related to musculature and nerves of the GI tract which communicate with the brain. In particular, the present invention provides a method for the selection of an agent effective for the treatment of an intestinal motility disorder, wherein said method comprises: a) a step of spatiotemporal (ST) mapping carried out on a gastrointestinal segment to analyse the effect of said agent on gastrointestinal motility; and b) a step of ex vivo nerve bundle recording carried out on a gastrointestinal segment to analyse the effect of said agent on mesenteric afferent nerve firing. Bacterial strains selected by the methods of the invention and the use of said bacterial strains in the treatment of intestinal motility disorders are also provided.
WO/2014/027929 UREA PRODUCTION PROCESS AND PLANT AND METHOD FOR MODERNIZING A UREA PRODUCTION PLANT||WO||20.02.2014|
||PCT/RU2013/000671||OTKRYTOE AKTSIONERNOE OBSCHESTVO RESEARCH & DESIGN INSTITUTE OF UREA AND ORGANIC SYNTHESIS PRODUCTS (OAO NIIK)||SERGEEV, Yury Andreevich|
The invention relates to processes and plants for producing urea from ammonia and carbon dioxide and can be used in the chemical industry and in the production of fertilizers. The process of producing urea by synthesizing same from carbon dioxide and ammonia at high temperatures and pressures with the two-stage distillation of the synthesis products (at 1.5-2.5 and 0.2-0.5 MPa) and the recirculation of unreacted ammonia and carbon dioxide in the form of an aqueous solution of carbon ammounium salts (CAS) additionally includes a stage for the adiabatic separation of the synthesis products at a pressure of 8-12 MPa, followed by distillation at the same pressure in a stream of carbon dioxide representing 40-60% of the total amount thereof introduced into the process; the corresponding plant is additionally provided with the equipment necessary to carry out this stage. The gases isolated during this distillation stage, together with a portion of the adiabatic separation gases, are subjected to absorption-condensation at the same pressure of 8-12 MPa and are returned, in the form of a CAS solution, for synthesis. The technical result achieved by using the proposed process and plant and by the modernization of a plant for the implementation of the proposed process is an increase in the degree of conversion of the initial reagents in the synthesis zone.